622
New York Genome Center
New York Genome Center (NYGC), a non-profi t center, will focus on sequencing,
bioinformatics, and genomic medicine. It is comprised of 11 collaborators, mostly
from New York City but also from institutions in other states. Through the unique
collaboration, scientists and physicians will share clinical and genomic data on a
large scale in studies aimed at identifying and validating biomarkers, understanding
the molecular basis of diseases, and speeding up the development of new diagnostic
and therapeutic technologies. It is using an initial $125 million investment to build
the 120,000 square-foot center in Manhattan to begin operations. NYGC is outfi tted
with technology from Illumina, one of its founding members. Roche has also joined
Illumina as a corporate member. The other founding members include Cold Spring
Harbor Laboratory; Columbia University; Cornell University/Weill Cornell Medical
College; Memorial Sloan-Kettering Cancer Center; Mount Sinai Medical Center;
New York-Presbyterian Hospital; New York University/NYU School of Medicine;
North Shore-LIJ Health System; The Jackson Laboratory; The Rockefeller
University; and Stony Brook University. The Hospital for Special Surgery is an asso-
ciate founding member. The partner institutions serve >5 million patients and offer
scientists a broad and diverse range of genetic variation that would be diffi cult to fi nd
in any other single region. The center’s core components will be its sequencing capa-
bilities and its bioinformatics labs, but it also will be home to a CLIA- certifi ed lab
for clinical research, an innovation center for developing new genomic technologies,
educational and training programs in genomics, and a philanthropic unit.
New York City is the largest concentration of medical and academic research
anywhere in the world. The diversity of the patient populations here is really impor-
tant. It provides a place where new products and tests can be developed for a variety
of ethnic groups and age groups for which different drugs and approaches might be
appropriate.
P4 Medicine Institute
The P4 Medicine Institute ( http://p4mi.org/ ) is driving innovative approaches to
disease prevention and maintenance of health and wellness by applying systems
biology to medicine and care delivery. P4 stands for predictive, preventive, partici-
patory and personalized medicine. P4Mi was co-founded in 2010 by the Institute for
Systems Biology and the Ohio State University Medical Center, which is develop-
ing more specifi c, cost-effective treatments for patients, creating new technologies
and tools that will defi ne wellness at a deep molecular level, and empowering indi-
viduals to take an active role in their health care. P4Mi is now joined by PeaceHealth,
a Washington-based not-for-profi t Catholic health care system, with major medical
centers and laboratories in Alaska, Washington and Oregon with approximately
15,000 employees.
20 Development of Personalized Medicine